How do Medibank (ASX:MPL) dividends compare to NIB?

How do the dividend yields of these 2 private healthcare insurers stack up for income investors?

man holding two stacks of coins varying in size representing a comparison of dividend yields between Medibank and NIB

Image source: Getty Images

Key points

  • Medibank Private and NIB are both ASX 200 health insurance heavyweights
  • Both offer robust dividend yields, complete with full franking
  • But which private health insurer comes out on top for income investors?

The Medibank Private Ltd (ASX: MPL) share price is enjoying a pretty positive day on the ASX boards this Friday. At the time of writing, the Medibank share price is up 0.3% at $3.29. That also puts this private health insurer at a robust 11.5% gain for the past 12 months. It also puts its trailing dividend yield at a solid 3.85%.

Given Medibank usually includes full franking credits with its dividends, that means this company is today offering a grossed-up yield of 5.5%. That's objectively not a bad yield from an ASX 200 dividend share. It's more than what Commonwealth Bank of Australia (ASX: CBA) shares are offering right now, for starters.

But how do Medibank dividends compare to those of ASX-listed arch rival NIB Holdings Limited (ASX: NHF)?

Well, let's check out the recent history of the Medibank dividend before we start the comparisons. So that 3.85% trailing yield comes from Medibank's 2 dividend payments doled out in 2021. The first was the interim dividend of 5.8 cents a share that shareholders received last March. The second was the final dividend of 6.9 cents paid in September.

Both payments were fully franked, as flagged earlier. Together, that equates to a total of 12.7 cents per share in dividends for 2021, a hearty increase over the 12 cents per share Medibank dividend paid in 2020. But this is not quite at the high watermark of 15.6 cents per share dividend that Medibank paid in 2019.

So how do those payments compare to that of NIB?

How do Medibank dividends compare to NIB?

Well, to kick things off, NIB shares currently have a trailing yield of 3.64%, based on the current share price of $6.59 that we see today. That grosses-up to 5.2% with full franking credits.

That yield comes from the interim dividend of 10 cents a share that we saw last April. As well as the final dividend of 14 cents per share paid out last October. Both payouts were fully franked. That equates to a 2021 total of 24 cents per share, a record high dividend from NIB.

So it appears that the Medibank dividend is the leader here (if only just) for income investors. We'll have to see if that holds up when both Medibank and NIB's 2022 dividends come through the door.

Medibank share price snapshot

While the Medibank share price is up a healthy 11.5% over the past 12 months, it has weakened in 2022. The share price has fallen by 4% since the year began.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended NIB Holdings Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air.
Healthcare Shares

Telix Pharmaceuticals vs Ramsay Healthcare: Which ASX healthcare stock made investors richer in 2026?

And find out which has the strongest upside ahead.

Read more »

Buy and sell written on red dice on top of stock market charts.
Broker Notes

Up 98%: Are CSL shares now a buy, hold or sell?

A leading expert provides his forecast for CSL’s rocketing shares.

Read more »

Doctor with stethoscope using a tablet in a hospital.
Broker Notes

What is this broker's view on Telix shares after yesterday's crash?

Here is the latest outlook from Bell Potter.

Read more »

Doctor with stethoscope holding a tablet and smiling.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can CSL continue delivering very healthy returns?

Read more »

Male and female scientists analysing data on a computer.
Healthcare Shares

Telix shares just crashed 12% on merger news. Time to buy the dip?

Integration, regulatory milestones and dilution are the real tests now.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

Sigma Healthcare vs Sonic Healthcare: Which ASX healthcare share wins?

I compare Sigma Healthcare and Sonic Healthcare to reveal which ASX healthcare share I think is the better buy right…

Read more »

A man surrounded by huge piles of paper looks through a magnifying glass at his computer screen.
Opinions

CSL shares are back near $180. Here's the level I'm watching

CSL shares are nearing a key technical level after a strong rebound.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Neuren Pharmaceuticals vs Telix Pharmaceuticals: Which healthcare stock is best?

How do Neuren Pharmaceuticals and Telix Pharmaceuticals stack up? Here’s my verdict on which ASX healthcare stock looks more compelling…

Read more »